Coronavirus vaccine - Stemirna Therapeutics/Tongji University
Latest Information Update: 05 Jan 2023
At a glance
- Originator Stemirna Therapeutics; Tongji University
- Developer Stemirna Therapeutics
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II COVID 2019 infections
Most Recent Events
- 11 Nov 2022 Stemirna Therapeutics completes a phase-I/II clinical trials in COVID-2019 infections (Prevention) in Laos (IM) (NCT05144139)
- 03 Dec 2021 Phase-I/II clinical trials in COVID-2019 infections (Prevention) in Laos (IM) (NCT05144139)
- 03 Dec 2021 Stemirna Therapeutics plans a phase I/II trial for COVID-19 infection (In adult, In the elderly, Prevention) in Laos (NCT05144139)